Amendments to the Claims

1. Cancelled.

2. Cancelled.

3. Cancelled.

4. Cancelled.

5. Cancelled.

6. Cancelled.

7. Cancelled.

8. Cancelled.

9. Cancelled.

10. Cancelled.

11. Cancelled.

11. Cancelled.

12. Cancelled.

13. Cancelled.

14. Cancelled.

15. Cancelled.

16. (Original) A process for preparing a compound of Formula XI



FORMULA XI

(R_{16} = $-CH_2F$ or $-CH_2F_2$) by reacting a compound of Formula IX



FORMULA IX

with sodium borohydride to produce a compound of Formula X



FORMULA X

and further reacting this compound with diethylamino sulfurtrifluoride to produce compound of Formula XI.

17. (Original) A process for preparing a compound of Formula XII



FORMULA XII

wherein R_{17} = $\diagdown\!=\!N\!-\!OH$ which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula IX



FORMULA IX

with hydroxylamine.

18. (Original) A process for preparing a compound of Formula XII



FORMULA XII

wherein R_{17} = $=N-NH_2$ which comprises reacting (S)-N-[[3-[3-Fluoro-4[N-1-[4-{2-furyl-(5-hydrazone)-methyl}]-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide with hydrazine hydrate.

19. (Original) A process for preparing a compound of Formula XII



FORMULA XII

wherein R_{17} = $=N-O-\overset{O}{\overset{\|}{C}}-NH-C_6H_4-CH_2COOCH_3$ which comprises reacting (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furyl-(5-aldoxime)methyl}] piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide with isocyanate.

20. (Original) A process for preparing a compound of Formula XII



FORMULA XII

wherein R_{17} = CN which comprises reacting (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-cyano)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide with trifilic anhydride and triethylamine.

21. (Original) A process for preparing a compound of Formula XII



FORMULA XII

wherein R17 =  which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[5-(1,3-dioxane)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide with 1,3-propane diol and BF_3 etherate.

22. (Original) A process for the preparation of the compound of Formula XIV



FORMULA XIV

wherein R_{18} = 
which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}] piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula IX



FORMULA IX

with Ag_2O to produce (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII followed by reacting (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl- (5-carboxyethyl)methyl)piperazinyl] phenyl]- 2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII



FORMULA XIII

with aqueous ammonia to produce Formula XIV.

23. (Original) A process for the preparation of the compound of Formula XIV



FORMULA XIV

wherein R_{18} = 

which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}] piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula IX



FORMULA IX

with Ag_2O to produce (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII followed by reacting (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl- (5-carboxyethyl)methyl)piperazinyl] phenyl]- 2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII



FORMULA XIII

with thionyl chloride to produce Formula XIV.

24. (Original) A process for the preparation of the compound of Formula XIV



FORMULA XIV

wherein R_{18} = 

which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}] piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula IX



FORMULA IX

with Ag_2O to produce (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII followed by reacting (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl- (5-carboxyethyl)methyl)piperazinyl] phenyl]- 2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII



FORMULA XIII

with morpholine in the presence of oxalyl chloride to produce Formula XIV.

25. (Currently Amended) A compound having the structure of Formula I



FORMULA I

and its pharmaceutically acceptable salts, enantiomers, diastereomers, or N-oxides, wherein

T is five- to seven-membered heterocyclic ring, aryl, substituted aryl, bound to the ring C with a linker W and the heterocyclic and aryl rings are further substituted by a group represented by R,

wherein R is selected from the group consisting of hydrogen, alkyl (C_{1-6}), halogen, -CN, COR_5,$COOR_5$, $N(R_6,R_7)$, CON (R_6, R_7), CH_2NO_2, NO_2, CH_2R_8, CHR_9, -CH = N-OR_{10}, -C=CH-R_5, wherein R_5 is selected from the group consisting of H, optionally substituted C_1-C_{12}, alkyl, C_{3-12}, cycloalkyl, aryl, heteroaryl; R_6 and R_7 are independently selected from the group consisting of H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy; R_8 and R_9 are independently selected from the group consisting of H, C_{1-6} alkyl, F, Cl, Br, C_{1-12} alkyl substituted with one or more of F, Cl, Br, I, OR_4, SR_4, $N(R_6,R_7)$ wherein R_4 is selected from the group consisting of H, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl substituted with one or more F, Cl, Br, I or OH and R_6 and R_7 are the same as defined earlier, R_{10} is selected from the

group consisting of H, optionally substituted from H, optionally substituted C_{1-12} alkyl, C_{3-512} cycloalkyl, C_{1-6}, alkoxy, C_{1-6} alkyl, aryl, heteroaryl;

n is 1;

X is N

Y and Z are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, and C_{3-12} cycloalkyl;

U and V are independently selected from the group consisting of hydrogen, optionally substituted C_{1-6} alkyl, F, Cl, Br, and C_{1-12} alkyl substituted with one or more of F, Cl, Br, I;

W is selected from the group CH_2, CO, ~~CH_2NH, $NHCH_2$, CH_2NHCH_2, $CH_2N(R_{11})CH_2$~~, -CO-CO-, ~~$CH_2(R_{11})N$ -; $CH(R_{11})$, S,~~ $CH_2(CO)$~~, $N(R_{11})$ wherein R_{11} is hydrogen, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl or heteroaryl~~;

R_1 is selected from the group consisting of - $NHC(=O)R_2$ wherein R_2 is hydrogen, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl substituted with one or more of F, Cl, Br, I or OH; $N(R_3, R_4)$; $-NR_2C(=S)R_3$; $-NR_2C(=S)SR_3$ wherein R_2 is the same as defined above and R_3 and R_4 are independently selected from the group consisting of H, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl substituted with one or more of F, Cl, Br, I or OH;

with the proviso that when R_1 is NHAc, and one of U or V is halogen, and W is (CO), and T is isoxazole, then R cannot be cyano, $(C(O)NH_2$, $C(O)N(CH_3)_2$, CO_2H, or CH_3, and when R_1 is NHAc, and one of U or V is halogen, and W is CH_2, and T is isoxazole, then R cannot be CH_3.

26. (Currently Amended) A compound having structure of Formula II



FORMULA II

and its pharmaceutically acceptable salts, enantiomers, diastereomers, or N-oxides, wherein

M= O, S, NH, N-CH_3;

X is N;

Y and Z are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, and C_{3-12} cycloalkyl;

U and V are independently selected from the group consisting of hydrogen, optionally substituted C_{1-6} alkyl, F, Cl, Br, and C_{1-12} alkyl substituted with one or more of F, Cl, Br, I;

W is selected from the group consisting of CH_2, CO, ~~CH_2NH, $NHCH_2$, CH_2NHCH_2, CH_2-N(R_{11})-CH_2-, CH_2-(R_{11})N-, CH(R_{11}), S,~~ CH_2(CO), ~~NH wherein R_{11} is optionally substituted with C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl except when M=S, Q=P=H, W=(C=O)~~ with the proviso that when M is sulphur, and when W is (CO), then Q and P cannot be hydrogen;

n is 1; and,

Q and P are independently selected from the group consisting of hydrogen, -CN, COR_5, $COOR_5$, N(R_6, R_7), CON(R_6,R_7), CH_2NO_2, NO_2, CH_2R_8, CHR_9, -CH=N-OR_{10}, C=CH-R_5, wherein R_5 is selected from the group consisting of H, optionally substituted C_{1-12}alkyl, C_{3-12} cycloalkyl, aryl, heteroaryl; R_6 and R_7 are independently selected from the group consisting of H, optionally

substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy; R_8 and R_9 are independently selected from the group consisting of H, C_{1-6} alkyl ,F, Cl, Br, C_{1-12} alkyl substituted with one or more of F, Cl, Br, I, OR_4, SR_4, wherein R_4 is selected from the group consisting of H, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl substituted with one or more F, Cl, Br, I or OH, $N(R_6, R_7)$, R_{10} is selected from the group consisting of H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl ~~except W= (CO), Q and P =H and M=S, wherein M = Sulphur and Oxygen~~ as shown by Formulae III and IV respectively,



FORMULA III



Formula IV

wherein P, Q, U, V, X , Y, Z, W and n in Formulae III and IV as defined earlier for Formula I.

27. (Currently Amended) A compound selected from the group consisting of

~~1.~~ (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furoyl) piperazinyl]]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide

~~2.~~ (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

~~3.~~ (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl-(5-carboxyethyl)methyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

~~4.~~ (S)-N-[[3-Fluoro-4-[N-1[4-(5-bromo-2-furoyl)]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide

~~5.~~ (S)-N-[[3-Fluoro-4-[N-1[4-(5-chloromethyl-2-furoyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

~~6.~~ (S)-N-[[3-Fluoro-4-[N-1[4-(5-nitro-2-furoyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide

~~7.~~ (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-(2-thienyl)dicarbonyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

~~8.~~ (S)-N[[3-[3-Fluoro-4-[N-1[4-(3-furoyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl] acetamide

~~9.~~ (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-bromo)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

~~10.~~ (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-chloro)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

~~11.~~ (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-furylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl] methyl]acetamide

~~12.~~ (S)-N-[[3-[3-Fluoro-4-[N-1[4-(2-thienylmethyl)]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

~~13.~~ (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-thienylacetyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl] methyl]acetamide

~~14.~~ (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(4-bromo)methyl}]piperazinyl] phenyl]-2 oxo-5-oxazolidinyl]methyl]acetamide

~~15.~~ (S)-N-[[3-[3-fluoro-4-[N-1-[4-{2-furyl-(5-nitro)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

~~16.~~ Hydrochloric salt of (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-nitro)methyl}]piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

~~17.~~ Citrate salt of (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-nitro)methyl}]piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

~~18.~~ (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-pyrrolylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

~~19.~~ (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(3-methyl)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

~~20.~~ (S)-N[[3-[3-Fluoro-4-[N-1[4-(3-furylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl] methyl]acetamide

~~21.~~ (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-methyl)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

~~22.~~ (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-pyrrole(1-methyl)methyl}]piperazinyl] phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

~~23.~~ (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-nitro)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

~~24.~~ (S)-N[[3-[3-Fluoro-4-[N-1[4-[2-furyl{5-(N-thiomorpholinyl)methyl}methyl]piperazinyl] phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

~~25.~~ (S)-N[[3-[3-Fluoro-4-[N-1[4-[2-furyl{5-(N-morpholinyl)methyl}methyl]]piperazinyl] phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

~~26.~~ (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-acetoxymethyl)methyl}]piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

~~27.~~ (S)-N-[[3-Fluoro-4-[N-1[4-{2-thienyl(5-bromo)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

~~28.~~ (S)-N-[[3-Fluoro-4-[N-1[4-(5-nitro-2-furylmethyl)piperazinyl] phenyl]- 2-oxo oxazolidinyl]methyl]dichloroacetamide

~~29.~~ (S)-N[[3-[3-Fluoro-4-[N-1[4-(5-nitro-2-thienoyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride

~~30.~~ (S)-N[[3-[3-Fluoro-4-[N-1[4-(2',2'- diphenyl-2' hydroxy acetyl)] piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

~~59.~~ (S)-N-[[3-[3-fluoro-4-[N-1{2-furyl-[4-(5-difluoromethyl) methyl] piperazinyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide.

~~60.~~ (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furyl-(5-aldoxime)methyl}] piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

~~61.~~ (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-aldoxime(methyl-4-(N-carboxyaminophenyl acetate) methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

~~62.~~ (S)-N-[[3-[3-Fluoro-4[N-1-[4-{2-furyl-(5-hydrazone)-methyl}]-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide

~~63.~~ (S)-N-[[3-[3-fluoro-4-[N-1{2-furyl-[4-(5-difluoromethyl) methyl}]piperazinyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide

~~64.~~ (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furyl-(5-aldoxime)methyl}] piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

~~65.~~ (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-aldoxime(methyl-4-(N-carboxyaminophenyl acetate) methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

~~66.~~ (S)-N-[[3-[3-Fluoro-4[N-1-[4-{2-furyl-(5-hydrazone)-methyl}]-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide

~~67.~~ (S)-N-[[3-[3-Fluoro-4-[N-1{2-furyl-[4-(5-hydroxymethyl)methyl}] piperazinyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

~~68.~~ (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-cyano)methyl}] piperazinyl]phenyl] -2-oxo-5-oxazolidinyl]methyl]acetamide

~~69.~~ (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

~~70.~~ (S)-N-[[3-Fluoro-4-[N-1[5-(1,3-dioxane)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

~~71.~~ (S)-N-[[3-Fluoro-4-[N-1[5-(formamido)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

~~72.~~ (S)-N-[[3-Fluoro-4-[N-1[5-(morpholine-1-carbonyl)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

~~73.~~ (S)-N-[[3-Fluoro-4-[N-1[5-(4-(tert butoxy carbonyl)amino piperidine)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

~~74.~~ (S)-N-[[3-Fluoro-4-[N-1[4-{(Z)-2-methoxyimino-2-(2-furyl)acetyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

28. (Previously Added) A pharmaceutical composition comprising the compound of claims 25, 26, or 27 and a pharmaceutically acceptable carrier.

29. (Previously Added) A pharmaceutical composition comprising a pharmaceutically effective amount of compound according to claims 25, 26 or 27, or a physiologically acceptable

acid addition salt thereof with a pharmaceutically acceptable carrier for treating microbial infections.

30. (Previously Added) A method of treating or preventing microbial infections in a mammal comprising administering to the said mammal, the pharmaceutical composition according to claim 29.

31. (Currently Amended) A process for preparing a compound of Formula I



FORMULA I

and its pharmaceutically acceptable salts, enantiomers, diastereomers, or N-oxides, wherein

T is five to seven membered heterocyclic ring, aryl, substituted aryl, bound to the ring **C** with a linker w and the heterocyclic and aryl rings are further substituted by a group represented by **R**,

wherein R is selected from the group consisting of hydrogen, –CN, COR_5,$COOR_5$, $N(R_6,R_7)$, CON (R_6, R_7), CH_2NO_2, NO_2, CH_2R_8, CHR_9, -CH = N-OR_{10}, -C=CH-R_5, wherein R_5 is selected from the group consisting of H, optionally substituted C_1-C_{12}, alkyl, C_{3-12}, cycloalkyl, aryl, heteroaryl, R_6 and R_7, are independently selected from the group consisting of H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy; R_8 and R_9 are independently selected from the group consisting of H, C_{1-6} alkyl, F, Cl, Br, C_{1-12} alkyl substituted with one or more of F, Cl, Br, I, OR_4, SR_4, $N(R_6,R_7)$ wherein R_4 is selected from the group consisting of H, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl substituted with one or more F, Cl, Br, I or OH and R_6 and R_7 are the same as defined earlier, R_{10} is selected from the group consisting of H, optionally substituted from H, optionally substituted C_{1-12} alkyl, C_{3-512} cycloalkyl, C_{1-6}, alkoxy, C_{1-6} alkyl, aryl, heteroaryl;

n is 1;

X is N;

Y and Z are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, and C_{3-12} cycloalkyl;

U and V are independently selected from the group consisting of hydrogen, optionally substituted C_{1-6} alkyl, F, Cl, Br, and C_{1-12} alkyl substituted with one or more of F, Cl, Br, I;

W is selected from the group consisting of CH_2, CO, ~~CH_2NH, $NHCH_2$, CH_2NHCH_2, CH_2-N (R_{11}) CH_2 -, CH_2 (R11) N -, CH (R_{11}), S,~~ CH_2(CO), NH ~~wherein R_{11} is optionally substituted with C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl~~; and

R_1 is selected from the group consisting of - NHC(=O)R_2 wherein R_2 is hydrogen, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl substituted with one or more of F, Cl, Br, I or OH; N(R_3, R_4) ; -$NR_2C(=S)$ R_3 : -$NR_2C(=S)SR3$ wherein R_2 is the same as defined above and R_3 and R_4 are independently selected from the group consisting of H, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl substituted with one or more of F, Cl, Br, I or OH,

which comprises reacting an amine compound of Formula V



FORMULA V

with a heterocyclic compound of Formula R-T-W- R_{12} wherein G in amines of Formula V is defined as NH and Y, Z, U, V, R_1, n, R, T and W are the same as defined earlier and R_{12} is a leaving group selected from the group consisting of <u>-CHO,</u> fluoro, chloro, bromo, SCH_3, -SO_2CH_3, -SO_2CF_3 or OC_6H_5;

with the proviso that when R_1 is NHAc, and one of U or V is halogen, and W is (CO), and T is isoxazole, then R cannot by cyano, $C(O)NH_2$, $C(O)N(CH_3)_2$, CO_2H, or CH_3, and when R_1 is NHAc, and one of U or V is halogen, and W is CH_2, and T is isoxazole, then R cannot be CH_3.

32. (Currently Amended) A process for preparing a compound of Formula I as claimed in claim 31, wherein $W=CH_2$ and R-T-W-R_{12} is a five membered heterocyclic ring with aldehyde group and the compound of Formula I is produced by reductive amination with the proviso that when R_1 is HHAc, and one of U or V is halogen, and W is CH_2, and T is isoxazole, then R cannot be CH_3.

33. (Previously Added) A process for preparing a compound of Formula I as claimed in claim 31, wherein W = CO and R-T-W-R_{12} is a five membered heterocyclic ring with carboxylic acid, and amino compound of Formula V is acylated with activated esters in presence of condensing agents comprising 1,3-dicyclohexylcarbodiimide (DCC) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC).

34. (Currently Amended) A process for the preparation of compound of Formula II



FORMULA II

wherein

n is 1;

X is N;

Y and Z are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, and C_{3-12} cycloalkyl;

U and V are independently selected from the group consisting of hydrogen, optionally substituted C_{1-6} alkyl, F, Cl, Br, and C_{1-12} alkyl substituted with one or more of F, Cl, Br, I;

W is selected from the group consisting of CH_2, CO, ~~$-CH_2NH$, $-NHCH_2$, $-CH_2NHCH_2$, $-CH_2-N(R_{11})CH_2-$, $-CH_2-(R11)N-$, $CH(R_{11})$, S,~~ CH_2(CO), NH ~~wherein R_{11} is optionally substituted with C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl~~; and

Q and P are independently selected from the group consisting of hydrogen, -CN, COR_5, $COOR_5$, N (R_6, R_7), CON (R_6,R_7), CH_2NO_2, NO_2, CH_2R_8, CHR_9, -CH=N-OR_{10}, C=CH-R_5, wherein R_5 is selected from the group consisting of H, optionally substituted C_{1-12}alkyl, C_{3-12} cycloalkyl, aryl, heteroaryl; R_6 and R_7 are independently selected from the group consisting of H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy; R_8 and R_9 are independently selected from the group consisting of H, C_{1-6} alkyl, F, Cl, Br, C_{1-12} alkyl substituted with one or more of F, Cl, Br, I, OR_4, SR_4,wherein R_4 is the same as defined before, N(R_6, R_7), R_{10} is selected from the group consisting of H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl ~~except W= (CO), Q and P =H.~~ with the proviso that when M is sulphur and W is (CO), then Q and P cannot be hydrogen;

wherein M = Sulphur is shown by compounds of Formula III,



FORMULA III

wherein P, Q, U, V, X, Y, Z, W and n in Formula III are the same as previously defined, wherein the process comprising reacting a compound of Formula V



FORMULA V

with a compound of Formula VI



FORMULA VI

wherein the transformation is carried out in the presence of carbon monoxide and a catalyst,

wherein P, Q, ~~R_{12}~~, Y, Z, ~~G~~, n, U and V are the same as defined earlier, R_{12} is a leaving group selected from the group consisting of -CHO, fluoro, chloro, bromo, SCH_3, $-SO_2CH_3$, $-SO_2CF_3$ or OC_6H_5, G is NH.

35. (Previously Added) A process for preparing a compound of Formula II as claimed in claim 34, in a solvent selected from the group consisting of dimethylformamide, dimethylacetamide, ethanol or ethylene glycol at a temperature in the range of -70°C to 180°C in the presence of a base selected from the group consisting of triethyl amine, diisopropyl amine, potassium carbonate and sodium bicarbonate.

36. (Previously Added) A process of preparing a compound of Formula II as claimed in claim 34, wherein Formula VI is furaldehyde and reductive alkylation of the amine of Formula V is performed with a reducing agent.

37. (Previously Added) A process for preparing a compound of Formula II as claimed in claim 34, wherein Formula VI is furoic acid.

38. (Currently Amended) A process for preparing a compound of Formula II as claimed in claim 34, wherein the compounds of Formula II having carbonyl link are prepared by reacting a heteroaromatic compound of the Formula VI ~~including N- methyl pyrrole~~ with the intermediate amine of Formula V in the presence of triphosgene or phosgene and carbonyl linkers are introduced between heteroaromatic compound comprising reacting 3- bromothiophene and amine of Formula V with carbon monoxide and the catalyst is selected from the group consisting of Pd $(PPh_3)_2Cl_2$ and extended chain pyrroles having dicarbonyl linkers are obtained by treatment of oxalyl chloride and amine of the Formula V.

39. (Cancelled)